The estimated Net Worth of Christopher Astle is at least $151 Thousand dollars as of 5 January 2024. Christopher Astle owns over 10,500 units of Zymeworks BC Inc stock worth over $151,214 and over the last 3 years Christopher sold ZYME stock worth over $0.
Christopher has made over 3 trades of the Zymeworks BC Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Christopher exercised 10,500 units of ZYME stock worth $127,050 on 5 January 2024.
The largest trade Christopher's ever made was exercising 10,500 units of Zymeworks BC Inc stock on 5 January 2024 worth over $127,050. On average, Christopher trades about 2,720 units every 78 days since 2022. As of 5 January 2024 Christopher still owns at least 12,497 units of Zymeworks BC Inc stock.
You can see the complete history of Christopher Astle stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1, and Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: